Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • Bitcoin USD

    64,768.16
    +502.66 (+0.78%)
     
  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • Dow

    37,986.40
    +211.02 (+0.56%)
     
  • Nasdaq

    15,282.01
    -319.49 (-2.05%)
     
  • Gold

    2,406.70
    +8.70 (+0.36%)
     
  • Crude Oil

    83.24
    +0.51 (+0.62%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Stock market today: Dow rides tech, Tesla to another weekly win; Fed meeting eyed

Investing.com -- The Dow stretched its weekly winning streak Friday, supported by tech and a Tesla-led jump in consumer stocks ahead of a widely expected Federal Reserve pause on rate hikes next week.

The Dow Jones Industrial Average gained 0.1%, or 43 points to notch a second-weekly gain, while the Nasdaq added 0.2%. The S&P 500, which entered a bull market a day earlier after closing up 20% from its October low, was up 0.2%.

Tesla Inc (NASDAQ:TSLA) jumped more than 4% to remain on track for an 11-day win streak as investors cheered news that General Motors is partnering with the electric vehicle maker to access its EV charging network.

The Tesla-GM collaboration will provide GM EV drivers with access to 12,000 Tesla superchargers, Wedbush says, noting that this is a “large monetization opportunity for the company in its supercharger story.”

ADVERTISEMENT

The opportunity adds to Tesla’s “growing sum-of-the-parts valuation that we now peg at $300 per share with its developing energy business along with its well-established EV machine,” Wedbush said after adding Tesla to its best ideas list.

General Motors Company (NYSE:GM) and Ford Motor (NYSE:F), which recently also struck a similar deal to access Tesla’s superchargers, were also higher.

Big tech also added to gains from a day earlier, riding the ongoing wave of bullish sentiment as Wall Street continues to talk up the opportunity of artificial intelligence for tech giants, which have the capital needed to gain a stronghold in the emerging AI industry.

"The larger technology companies can absorb the costs of building these large language models, afford some of these computing costs, as well as comply with regulation,” Goldman Sachs said in a recent blog post.

Adobe (NASDAQ:ADBE), meanwhile, continued to rack up gains ahead of its quarterly results due Jun. 15 after Wells Fargo upgraded the stock to Overweight from Buy amid optimism that its AI progress will likely boost growth.

DocuSign (NASDAQ:DOCU) gave up gains, falling more than 2% after its better-than-expected quarterly results were overshadowed by cautious remarks from CEO Allan C. Thygesen who flagged slowing growth and a cautious customer backdrop.

Braze (NASDAQ:BRZE), meanwhile, rallied 16% after reporting quarterly results that were better than feared, prompting positive commentary from Goldman Sachs, which reiterated its Buy rating on the stock, citing potential AI-driven market share gains.

On the political front, Donald Trump is facing 37 criminal counts, an unsealed indictment showed Friday, alleging the former president violated the Espionage Act through "willful retention" of classified documents.

The second week of gains in the broader market comes just ahead of inflation data on Monday and the Fed's two-day meeting starting Tuesday.

About 70% of traders expect the Fed to keep rates steady on Jun. 14, according to Investing.com's Fed Rate Monitor Tool

Related Articles

Stock market today: Dow rides tech, Tesla to another weekly win; Fed meeting eyed

White House welcomes Tesla to take advantage of federal dollars

US Chamber of Commerce sues over government's drug pricing power